Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 13, 2004. The report primarily details corporate governance activities, including changes in directors' interests and a share repurchase transaction, rather than providing comprehensive financial results for a fiscal period.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to a specific share buyback transaction:
- Shares Purchased: 850,000 Ordinary Shares.
- Purchase Date: May 12, 2004.
- Price per Share: 1,170.93 pence.
- Treasury Holdings Post-Purchase: 11,790,000 shares.
- Shares in Issue (excluding treasury): 5,921,528,598 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through a treasury buyback authorized by shareholders at the Annual General Meeting on May 19, 2003. Additionally, there were minor adjustments to directors' interests:
- SmithKline Beecham Employee Benefit Trust: 156 Ordinary shares were transferred to a participant in the Unapproved Share Match Plan on May 12, 2004. Director John Coombe holds an interest in the fund consistent with other non-US employees.
- US Retirement Savings Plan: A re-valuation on May 7, 2004, at $43.06 per share resulted in a decrease in the notional allocation of Ordinary Share ADRs for Dr. J.P. Garnier (6 shares) and Dr. T. Yamada (2 shares).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Key Facts for Investor Verification
- Verify the total cost of the 850,000 share repurchase against the reported price of 1,170.93 pence per share.
- Confirm the updated total share count (5,921,528,598 in issue) against subsequent filings to ensure accuracy of treasury holdings.
- Review the impact of the share buyback on earnings per share (EPS) in the next quarterly or annual report.
- Monitor the SmithKline Beecham Employee Benefit Trust for further share transfers affecting director interests.